Immunomedics (IMMU) : 2 analysts are covering Immunomedics (IMMU) and their average rating on the stock is 2, which is read as a Buy. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Immunomedics (NASDAQ:IMMU): The stock opened at $2.39 on Wednesday but the bulls could not build on the opening and the stock topped out at $2.45 for the day. The stock traded down to $2.34 during the day, due to lack of any buying support eventually closed down at $2.39 with a loss of -0.42% for the day. The stock had closed at $2.40 on the previous day. The total traded volume was 1,248,446 shares.
Also, Brokerage firm Wells Fargo downgrades its rating on Immunomedics (NASDAQ:IMMU). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on June 21, 2016. The company shares have dropped -38.14% from its 1 Year high price. On Jun 2, 2016, the shares registered one year high at $5.05 and the one year low was seen on Sep 29, 2015. The 50-Day Moving Average price is $3.39 and the 200 Day Moving Average price is recorded at $2.82.
Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Companys technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.